Abstract: The present disclosure relates to CRISPR-Cas10 systems and methods for phage genome editing.

Abstract: This disclosure relates to tumor-targeted drug carriers that lead to improved anti-tumor efficacy by efficient delivery of a cytotoxic agent to the tumor microenvironment. Aspects of the disclosure relate to a polypeptide comprising an albumin or IgG Fc domain polypeptide operatively linked to a collagen binding domain. Further aspects relate to a composition comprising a polypeptide, nucleic acid, or cell of the disclosure.

Abstract: The present invention discloses a composition of an albumin-free, serum-free medium suited for culturing human hematopoietic stem cells and an albumin-free culturing method. According to the present invention, a method of culturing human hematopoietic stem cells is provided which comprises bringing human hematopoietic stem cells into contact with PVA and a PI3K activator.

Abstract: Method and devices are provided for assessing tissue samples from a plurality of tissue sites in a subject using molecular analysis. In certain aspects, devices of the embodiments allow for minimally invasive collection of liquid tissue samples and delivery of the samples for mass spectrometry analysis.

Abstract: A method can be executed by at least one processor of a computer to generate synthetic Integrated Circuit (IC) layout patterns, where the method can optionally include accessing attribute values of the IC layout pattern features generated using IC layout patterns from at least one at least one previous generation semiconductor fabrication technology node.

Abstract: Provided herein are block copolymers comprising a hydrophilic polymer segment and a hydrophobic polymer segment, wherein the hydrophilic polymer segment comprises a polymer selected from the group consisting of: poly(ethylene oxide) (PEO), poly(methacrylate phosphatidyl choline) (MPC), and polyvinylpyrrolidone (PVP), wherein the hydrophobic polymer segment comprises wherein R? is —H or —CH3, wherein R is —NR1R2, wherein R1 and R2 are alkyl groups, wherein R1 and R2 are the same or different, wherein R1 and R2 together have from 5 to 16 carbons, wherein R1 and R2 may optionally join to form a ring, wherein n is 1 to about 10, and wherein x is about 20 to about 200 in total. Also provided are pH-sensitive micelle compositions for therapeutic and diagnostic applications.

Abstract: Methods for identifying and treating cancers that are DNA repair, such as homologous recombination (HR) repair, defective or sensitive to PARP inhibitors or platinum-based therapy. In some aspects, DNA repair, such as HR repair, defective cancers are treated with a PARP inhibitor therapy or cisplatin. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided.

Abstract: Systems and methods are described for treating distal radius fractures using a plating system. In an aspect, a distal radius plating system includes a volar plate body for interfacing with a volar side of a distal portion of a radius bone. The volar plate body has a volar head portion extending from the volar plate body and terminating at a distal edge, the volar head portion including a first set of apertures to receive fixation fasteners therethrough to fix to the radius bone. The distal radius plating system also includes a radial longitudinal portion extending from a radial edge of the volar plate body to interface with the radial styloid of the radius bone while the volar plate body is positioned on the volar side of the distal portion of the radius bone.

Abstract: Compositions and methods of transplanting cells by grafting strategies into solid organs (especially internal organs) are provided. These methods and compositions can be used to repair diseased organs or to establish models of disease states in experimental hosts. The method involves attachment onto the surface of a tissue or organ, a patch graft, a “bandaid-like” covering, containing epithelial cells with supporting early lineage stage mesenchymal cells. The cells are incorporated into soft gel-forming biomaterials prepared under serum-free, defined conditions comprised of nutrients, lipids, vitamins, and regulatory signals that collectively support stemness of the donor cells. The graft is covered with a biodegradable, biocompatible, bioresorbable backing used to affix the graft to the target site. The cells in the graft migrate into and throughout the tissue such that within a couple of weeks they are uniformly dispersed within the recipient (host) tissue.

Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.

Abstract: Example embodiments allow for networks of hybrid controllers that can be computed efficiently and that can adapt to changes in the system(s) under control. Such a network includes at least one hybrid controller that includes a dynamic sub-controller and a learned system sub-controller. Information about the ongoing performance of the system under control is provided to both the hybrid controller and to an over-controller, which provides one or more control inputs to the hybrid controller in order to modify the ongoing operation of the hybrid controller. These inputs can include the set-point of the hybrid controller, one or more parameters of the dynamic controller, and an update rate or other parameter of the learned system controller. The over-controller can control multiple hybrid controllers (e.g., controlling respective sub-systems of an overall system) and can, itself, be a hybrid controller.

Abstract: Disclosed herein are antigen-capturing nanoparticles. Specifically, the subject matter contained herein pertains to novel nanoparticles that can capture a multitude of tumor antigens that are released from tumor cells. Also, provided herein are methods for preparing the antigen-capturing nanoparticles and methods for the treatment of disease in a subject comprising administering the antigen-capturing nanoparticles.

Abstract: The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.

Abstract: A vibration-driven energy harvesting device includes: a first vibration-driven energy harvesting assembly constituted with a first fixed comb tooth portion and a first movable comb tooth portion that are interdigitated with each other; a second vibration-driven energy harvesting assembly constituted with a second fixed comb tooth portion and a second movable comb tooth portion that are interdigitated with each other; a first output electrode connected to the first vibration-driven energy harvesting assembly; and a second output electrode connected to the second vibration-driven energy harvesting assembly, wherein: an output of the first vibration-driven energy harvesting assembly is different from an output of the second vibration-driven energy harvesting assembly.

Abstract: Hybrid organic/inorganic coating compositions of nanometer thickness are described, where the organic layer is a clay-containing layer comprising a clay and a hydrophilic polymer and the inorganic layer is a metal-containing layer comprising a metal with a refractive index greater than 1.5, where the coating compositions allow for the generation and tenability of iridescent color through control of the coat thickness.

Abstract: In one embodiment, an electromagnetic soft actuator includes a first soft outer member comprising a soft internal electrically conductive coil, a second soft outer member comprising a soft internal electrically conductive coil, and a soft inner shaft on which the first and second soft outer members are mounted, the first and second soft outer members being linearly displaceable along a length of the soft inner shaft, the soft inner shaft comprising a permanent magnet, wherein the first and second outer members linearly move under an electromagnetic force relative to the soft inner shaft and each other when an electric current is applied to the soft internal electrically conductive coils.

Abstract: Disclosed herein are methods for patterning two-dimensional atomic layer materials, the methods comprising: illuminating a first location of an optothermal substrate with electromagnetic radiation, wherein the optothermal substrate converts at least a portion of the electromagnetic radiation into thermal energy, and wherein the optothermal substrate is in thermal contact with a two-dimensional atomic layer material; thereby: generating an ablation region at a location of the two-dimensional atomic layer material proximate to the first location of the optothermal substrate, wherein at least a portion of the ablation region has a temperature sufficient to ablate at least a portion of the two-dimensional atomic layer material within the ablation region, thereby patterning the two-dimensional atomic layer material. Also disclosed herein are systems for performing the methods described herein, patterned two-dimensional atomic layer materials made by the methods described herein and methods of use thereof.

Abstract: Lipid particles containing a nucleic acid, devices and methods for making the lipid particles, and methods for using the lipid particles.

Abstract: Provided herein are cryopreservation compositions and methods for cells of any kind, including for cells for adoptive cell therapy that are off-the-shelf cells. The cells for cryopreservation may be expanding NK cells expressing chimeric antigen receptors. In specific cases, the cryopreservation media comprises a cryoprotectant, such as DMSO, glycerol or hydroxyethol starch; serum or a non-serum alternative, such as platelet lysate; and one or more cytokines that are either natural, modified, synthetic, or recombinant.

Abstract: Systems and methods for efficient and automatic determination of radiation beam configurations for patient-specific radiation therapy planning are disclosed. According to an aspect, a method includes receiving data based on patient information and geometric characterization of one or more organs at risk proximate to a target volume of a patient. The method includes determining automatically one or more radiation treatment beam configuration sets. Further, the method includes presenting the determined one or more radiation beam configuration sets via a user interface.